LATS2

Across TCGA pan-cancer cohorts, LATS2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LATS2 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher LATS2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LATS2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

BRCA, MESO, and COAD are the cancer types where LATS2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.335	0.924	<.001	36	view →
MESO	DFS	Median	All	0.109	0.378	<.001	27	view →
COAD	OS	Median	All	0.240	0.693	.007	16	view →
UCEC	DFS	Median	All	0.960	0.825	.010	14	view →
STAD	DFS	Median	II,III,IV	0.887	0.375	.045	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LATS2–BRCA (OS)

Open the BRCA breakdown →